IceCure Medical (ICCM) to Release Quarterly Earnings on Wednesday

IceCure Medical Ltd. (ICCM), a medical device company headquartered in Israel, specializes in the development and commercialization of the IceSense2 Pro system for the treatment of soft tissue diseases using controlled cold therapy. The company's innovative technology utilizes precise and localized cryoablation, which is a minimally invasive procedure that destroys unwanted tissue using extreme cold.

On Wednesday, IceCure Medical is scheduled to release its financial results for the third quarter of 2022. This announcement will provide investors and stakeholders with essential insights into the company's recent financial performance and business developments.

The IceSense2 Pro system is designed for the treatment of various soft tissue conditions such as fibroids, hemangiomas, and other benign and malignant tumors. The system's precision and minimal invasiveness offer several advantages over traditional surgical methods, including reduced recovery time, fewer complications, and lower overall healthcare costs.

In the second quarter of 2022, IceCure Medical reported a revenue increase of 11% compared to the same period in 2021. The company also announced that it had received CE Mark approval for its IceSense2 Pro system for the treatment of soft tissue sarcomas, expanding its indications for use in Europe.

As of now, IceCure Medical has installed over 100 systems worldwide and has treated more than 15,000 patients with its technology. The company's focus on expanding its global reach and increasing market penetration is expected to contribute significantly to its growth in the coming quarters.

The upcoming quarterly earnings report will provide investors with an update on IceCure Medical's financial performance, including revenue growth, gross margins, operating expenses, and net income or loss. Additionally, the report may include updates on regulatory approvals, clinical trials, and strategic partnerships that could impact the company's future growth prospects.

Stay tuned for more information following IceCure Medical's third-quarter earnings release on Wednesday.